Clinical trialNCT01008475CompletedPhase 1/PHASE2Interventional

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

SponsorMerck KGaA, Darmstadt, GermanyEnrollment232Metastatic Colorectal Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Medical Responsible
Merck KGaA, Darmstadt, Germany
Study Director
clinicaltrials.gov ↗
Prof. Josep Tabernero
HU Vall d' Hebron, Servei d'oncologia. E difici General
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

62 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Research Site
Brussels, Belgium
Research Site
Edegem, Belgium
Research Site
Ghent, Belgium
Research Site
Leuven, Belgium

Bulgaria

Research Site
Sofia, Bulgaria

Cyprus

Research Site
Stróvolos, Nicosia, Cyprus

Czechia

Research Site
Brno, Czechia
Research Site
Hořovice, Czechia
Research Site
Kutná Hora, Czechia
Research Site
Olomouc, Czechia
Research Site
Pardubice, Czechia
Research Site
Prague, Czechia

Germany

Research Site
Dresden, Germany
Research Site
Essen, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Hamburg, Germany
Research Site
Hanover, Germany
Research Site
Heilbronn, Germany
Research Site
Landshut, Germany
Research Site
Leipzig, Germany
Research Site
Munich, Germany
Research Site
Recklinghausen, Germany
Research Site
Ulm, Germany

Greece

Research Site
Thessaloniki, Cyprus, Greece
Research Site
Mournies Chania, Greece

Hungary

Research Site
Budapest, Hungary
Research Site
Győr, Hungary
Research Site
Kecskemét, Hungary
Research Site
Miskolc, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Szolnok, Hungary

Israel

Research Site
Haifa, Israel
Research Site
Jerusalem, Israel
Research Site
Ramat Gan, Israel
Research Site
Rehovot, Israel
Research Site
Tel Aviv, Israel

Poland

Research Site
Elblag, Poland
Research Site
Gdansk, Poland
Research Site
Gliwice, Poland
Research Site
Lodz, Poland

22 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cetuximab →EMD 525797Irinotecan →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2009
Primary completion: 30 Apr 2015
Completion: 30 Apr 2015
Last update posted: 30 Mar 2016
Registered enrollment: 232
Registry id: NCT01008475

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.